These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28729955)

  • 61. Identification and Analysis of the Blood lncRNA Signature for Liver Cirrhosis and Hepatocellular Carcinoma.
    Xia Q; Shu Z; Ye T; Zhang M
    Front Genet; 2020; 11():595699. PubMed ID: 33365048
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Identification of diagnostic long non‑coding RNA biomarkers in patients with hepatocellular carcinoma.
    Li G; Shi H; Wang X; Wang B; Qu Q; Geng H; Sun H
    Mol Med Rep; 2019 Aug; 20(2):1121-1130. PubMed ID: 31173205
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Construction of a long non-coding RNA-associated ceRNA network reveals potential prognostic lncRNA biomarkers in hepatocellular carcinoma.
    Yan Y; Yu J; Liu H; Guo S; Zhang Y; Ye Y; Xu L; Ming L
    Pathol Res Pract; 2018 Dec; 214(12):2031-2038. PubMed ID: 30316688
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A Three Long Noncoding RNA-Based Signature for Oral Squamous Cell Carcinoma Prognosis Prediction.
    Zhao C; Zou H; Wang J; Shen J; Liu H
    DNA Cell Biol; 2018 Nov; 37(11):888-895. PubMed ID: 30234381
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Identification and Verification of a Glycolysis-Related lncRNA Prognostic Signature for Hepatocellular Carcinoma.
    Qiu F; Yu G; Li M; Li Z; Zhang Q; Mu X; Cheng Y; Zhai P; Liu Q
    Horm Metab Res; 2024 May; ():. PubMed ID: 38772393
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
    Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
    World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comprehensive analysis of differential expression profiles of mRNAs and lncRNAs and identification of a 14-lncRNA prognostic signature for patients with colon adenocarcinoma.
    Xing Y; Zhao Z; Zhu Y; Zhao L; Zhu A; Piao D
    Oncol Rep; 2018 May; 39(5):2365-2375. PubMed ID: 29565464
    [TBL] [Abstract][Full Text] [Related]  

  • 68. lncRNAs as prognostic molecular biomarkers in hepatocellular carcinoma: a systematic review and meta-analysis.
    Zheng C; Liu X; Chen L; Xu Z; Shao J
    Oncotarget; 2017 Aug; 8(35):59638-59647. PubMed ID: 28938667
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A three-lncRNA signature derived from the Atlas of ncRNA in cancer (TANRIC) database predicts the survival of patients with head and neck squamous cell carcinoma.
    Cao W; Liu JN; Liu Z; Wang X; Han ZG; Ji T; Chen WT; Zou X
    Oral Oncol; 2017 Feb; 65():94-101. PubMed ID: 28109476
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A three‑lncRNA signature for prognosis prediction of acute myeloid leukemia in patients.
    Wang F; Tian X; Zhou J; Wang G; Yu W; Li Z; Fan Z; Zhang W; Liang A
    Mol Med Rep; 2018 Aug; 18(2):1473-1484. PubMed ID: 29901168
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Differentially Expressed lncRNAs in Gastric Cancer Patients: A Potential Biomarker for Gastric Cancer Prognosis.
    Tian X; Zhu X; Yan T; Yu C; Shen C; Hong J; Chen H; Fang JY
    J Cancer; 2017; 8(13):2575-2586. PubMed ID: 28900495
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Exploring a four-gene risk model based on doxorubicin resistance-associated lncRNAs in hepatocellular carcinoma.
    Zhang Z; Chen W; Luo C; Zhang W
    Front Pharmacol; 2022; 13():1015842. PubMed ID: 36457707
    [No Abstract]   [Full Text] [Related]  

  • 73. Long non-coding RNAs are differentially expressed in hepatocellular carcinoma cell lines with differing metastatic potential.
    Fang TT; Sun XJ; Chen J; Zhao Y; Sun RX; Ren N; Liu BB
    Asian Pac J Cancer Prev; 2014; 15(23):10513-24. PubMed ID: 25556502
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Title: Multi-Omics and Immune Landscape of Proliferative LncRNA Signatures: Implications for Risk Stratification and Immunotherapy in Hepatocellular Carcinoma.
    Liu C; Gao J; Yang D; Yu Q; Zhang S
    Front Pharmacol; 2022; 13():907433. PubMed ID: 35662721
    [No Abstract]   [Full Text] [Related]  

  • 75. Comprehensive Analysis of a Competing Endogenous RNA Network Identifies Seven-lncRNA Signature as a Prognostic Biomarker for Melanoma.
    Liu N; Liu Z; Liu X; Chen H
    Front Oncol; 2019; 9():935. PubMed ID: 31649871
    [TBL] [Abstract][Full Text] [Related]  

  • 76. lncRNA-D16366 Is a Potential Biomarker for Diagnosis and Prognosis of Hepatocellular Carcinoma.
    Chao Y; Zhou D
    Med Sci Monit; 2019 Sep; 25():6581-6586. PubMed ID: 31475695
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prediction of clinical outcome and survival in soft-tissue sarcoma using a ten-lncRNA signature.
    He RQ; Wei QJ; Tang RX; Chen WJ; Yang X; Peng ZG; Hu XH; Ma J; Chen G
    Oncotarget; 2017 Oct; 8(46):80336-80347. PubMed ID: 29113307
    [TBL] [Abstract][Full Text] [Related]  

  • 78. RNA-Sequencing Data Reveal a Prognostic Four-lncRNA-Based Risk Score for Bladder Urothelial Carcinoma: An in Silico Update.
    He RQ; Huang ZG; Li TY; Wei YP; Chen G; Lin XG; Wang QY
    Cell Physiol Biochem; 2018; 50(4):1474-1495. PubMed ID: 30359990
    [TBL] [Abstract][Full Text] [Related]  

  • 79. TP53 Mutation Related and Directly Regulated lncRNA Prognosis Markers in Hepatocellular Carcinoma.
    Zhang X; Fu Z; Zhang X
    Onco Targets Ther; 2021; 14():4427-4437. PubMed ID: 34408439
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Meta-analysis of the prognostic value of abnormally expressed lncRNAs in hepatocellular carcinoma.
    Qu Z; Yuan CH; Yin CQ; Guan Q; Chen H; Wang FB
    Onco Targets Ther; 2016; 9():5143-52. PubMed ID: 27574455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.